| Trial ID: | L2318 |
| Source ID: | NCT01095822
|
| Associated Drug: |
Aliskiren + Valsartan
|
| Title: |
Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: Aliskiren + Valsartan
|
| Outcome Measures: |
Primary: How therapy with valsartan (160mg/daily) in combination with aliskiren (150-300mg/daily) affects platelet/coagulation/fibrinolytic biomarkers in recently diagnosed hypertensive patients with type 2 diabetes mellitus., 4 weeks | Secondary: Whether combination therapy is superior over monotherapy with aliskiren with regard to the improvement of hemostatic biomarkers (platelet aggregation, expression of GP IIb/IIIa, and plasma levels of antithrombin-III)., 4 weeks
|
| Sponsor/Collaborators: |
Sponsor: HeartDrug Research LLC | Collaborators: Novartis
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2010-03
|
| Completion Date: |
2011-03
|
| Results First Posted: |
|
| Last Update Posted: |
2010-03-30
|
| Locations: |
Dr. Pokov's Polyclinic. 6821 Reisterstown Road Suite 206, Baltimore, Maryland, 21215, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01095822
|
